• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Transient Ischemic Attack Market Size

    ID: MRFR/Pharma/3590-CR
    226 Pages
    Rahul Gotadki
    July 2019

    Transient Ischemic Attack Market Research Report Information by Diagnosis (Imaging Techniques), Treatment (Surgery and Drugs), Age Groups (0–18 years and above), End-User and Region (Americas, Europe, Asia-Pacific and the Middle East & Africa) - Forecast till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Transient Ischemic Attack Market Infographic
    $ 4,950.0
    $ 5,950.0
    $ 7,250.0

    Transient Ischemic Attack Size

    Transient Ischemic Attack Market Growth Projections and Opportunities

    The transient ischemic attack (TIA) market is a significant aspect of healthcare, focusing on the prevention, diagnosis, and treatment of temporary disruptions in blood flow to the brain. Often referred to as "mini-strokes," TIAs are warning signs of potential strokes and require prompt medical attention to prevent more severe neurological damage. This market segment is vital due to the serious consequences associated with TIAs, including an increased risk of subsequent strokes, cognitive impairment, and disability. As awareness of TIAs grows among healthcare professionals and the general population, there is a growing demand for effective strategies to identify and manage these transient events.

    Key players in the TIA market include pharmaceutical companies, medical device manufacturers, diagnostic imaging providers, and healthcare facilities specializing in stroke care. Pharmaceutical interventions play a crucial role in preventing recurrent TIAs and strokes by targeting underlying risk factors such as hypertension, hyperlipidemia, and atrial fibrillation. Medications such as antiplatelet agents (e.g., aspirin, clopidogrel), anticoagulants, statins, and blood pressure-lowering drugs are commonly prescribed to reduce the risk of clot formation, improve blood flow, and stabilize atherosclerotic plaques in the arteries supplying the brain.

    In addition to pharmaceutical interventions, medical devices and diagnostic tools play a crucial role in the TIA market by enabling healthcare providers to accurately diagnose TIAs, assess stroke risk, and guide treatment decisions. Advanced imaging modalities such as magnetic resonance imaging (MRI), computed tomography (CT), and carotid ultrasound are used to visualize blood flow in the brain and identify potential causes of TIA symptoms, such as arterial stenosis or emboli. These imaging techniques help clinicians differentiate between TIAs and other neurological conditions, allowing for timely intervention and risk stratification.

    Another important aspect of the TIA market is rehabilitation and secondary prevention strategies aimed at reducing the risk of recurrent TIAs and strokes. Rehabilitation programs may include physical therapy, occupational therapy, speech therapy, and cognitive rehabilitation to address deficits in motor function, activities of daily living, communication, and cognitive abilities. Lifestyle modifications, such as smoking cessation, dietary changes, exercise, and weight management, are also emphasized to control modifiable risk factors and improve overall cardiovascular health.

    The TIA market is influenced by various factors, including demographic trends, epidemiological patterns, healthcare policies, and technological advancements. With an aging population and a growing prevalence of risk factors such as obesity, diabetes, and hypertension, the burden of TIAs and strokes is expected to increase globally. As a result, there is a growing emphasis on preventive measures, early detection, and comprehensive stroke care to reduce the societal and economic impact of these neurological events.

    Technological innovations are driving advancements in the diagnosis and treatment of TIAs, with emerging trends such as telemedicine, artificial intelligence (AI), and remote monitoring showing promise in improving access to care and optimizing treatment outcomes. Telestroke programs enable remote consultation and decision-making between stroke specialists and healthcare providers in underserved areas, facilitating timely administration of thrombolytic therapy and other acute interventions. AI algorithms are being developed to analyze medical imaging data and assist radiologists in detecting subtle abnormalities indicative of TIAs, allowing for faster and more accurate diagnoses.

    Transient Ischemic Attack Market Size Graph

    Market Summary

    The Global Transient Ischemic Attack Market is projected to grow from 0.12 USD Billion in 2024 to 0.38 USD Billion by 2035.

    Key Market Trends & Highlights

    Transient Ischemic Attack Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate (CAGR) of 11.0% from 2025 to 2035.
    • By 2035, the market valuation is anticipated to reach 0.38 USD Billion, indicating robust growth potential.
    • In 2024, the market is valued at 0.12 USD Billion, reflecting the current demand for TIA management solutions.
    • Growing adoption of advanced diagnostic technologies due to increasing awareness of transient ischemic attacks is a major market driver.

    Market Size & Forecast

    2024 Market Size 0.12 (USD Billion)
    2035 Market Size 0.38 (USD Billion)
    CAGR (2025-2035) 11.0%
    Largest Regional Market Share in 2024 latin_america)

    Major Players

    Koninklijke Philips NV (Netherlands), Stryker Corporation (US), Johnson & Johnson Services Inc (US), Boston Scientific Corporation (US), Sanofi (France), Bayer AG (Germany), Pfizer Inc (US), Siemens AG (US), F. Hoffmann-La Roche AG (Switzerland), GE Healthcare (UK), Penumbra Inc (California), Medtronic PLC (Ireland), Abbott Laboratories (US), Merck & Co., Inc (US), Boehringer Ingelheim GmbH (Germany)

    Market Trends

    The increasing prevalence of transient ischemic attacks underscores the urgent need for enhanced preventive strategies and effective treatment options to mitigate long-term neurological damage.

    Centers for Disease Control and Prevention (CDC)

    Transient Ischemic Attack Market Market Drivers

    Aging Population

    The demographic shift towards an aging population is a crucial factor driving the Global Transient Ischemic Attack Market Industry. As individuals age, the risk of cerebrovascular diseases, including TIAs, escalates. The United Nations projects that by 2030, the global population aged 60 years and older will reach 1.4 billion, creating a larger cohort susceptible to TIAs. This demographic trend necessitates enhanced healthcare services and interventions tailored to older adults, thereby fostering market expansion. The increasing burden of TIAs among the elderly population underscores the importance of developing targeted therapies and preventive measures.

    Rising Incidence of Stroke

    The increasing prevalence of stroke globally is a pivotal driver for the Global Transient Ischemic Attack Market Industry. As per recent health statistics, stroke remains one of the leading causes of morbidity and mortality worldwide. The World Health Organization indicates that approximately 15 million people suffer from stroke annually, with a significant portion experiencing transient ischemic attacks as precursors. This alarming trend underscores the necessity for enhanced diagnostic and therapeutic interventions, thereby propelling market growth. The Global Transient Ischemic Attack Market is projected to reach 0.12 USD Billion in 2024, reflecting the urgent need for effective management strategies.

    Market Trends and Projections

    The Global Transient Ischemic Attack Market Industry is witnessing notable trends that indicate a robust growth trajectory. Projections suggest that the market will expand from 0.12 USD Billion in 2024 to 0.38 USD Billion by 2035, reflecting a compound annual growth rate of 11.0% from 2025 to 2035. This growth is driven by various factors, including advancements in medical technology, increased awareness, and an aging population. The market dynamics are influenced by the evolving healthcare landscape, necessitating continuous adaptation by stakeholders to meet the demands of TIA management.

    Regulatory Support and Funding

    Government initiatives and regulatory support play a vital role in shaping the Global Transient Ischemic Attack Market Industry. Various health authorities are implementing policies aimed at improving stroke care and funding research for innovative treatments. For example, the National Institutes of Health in the United States allocates substantial resources to stroke research, which indirectly benefits TIA management. Such funding encourages the development of new therapies and technologies, thereby enhancing patient care. This supportive regulatory environment is expected to facilitate market growth, as stakeholders are more inclined to invest in TIA-related innovations.

    Increased Awareness and Education

    Growing awareness regarding transient ischemic attacks and their implications is significantly influencing the Global Transient Ischemic Attack Market Industry. Public health campaigns and educational initiatives by health organizations aim to inform individuals about the symptoms and risks associated with TIAs. This heightened awareness encourages early medical intervention, which is essential for preventing subsequent strokes. As a result, healthcare systems are increasingly prioritizing TIA management, leading to a surge in demand for related services and products. The market is expected to experience a compound annual growth rate of 11.0% from 2025 to 2035, driven by these educational efforts.

    Advancements in Medical Technology

    Technological innovations in medical devices and diagnostic tools are transforming the landscape of the Global Transient Ischemic Attack Market Industry. The advent of portable imaging technologies and telemedicine solutions facilitates timely diagnosis and treatment, which is crucial for TIA patients. For instance, advanced MRI techniques enable rapid identification of ischemic episodes, thereby improving patient outcomes. Furthermore, the integration of artificial intelligence in predictive analytics is enhancing risk stratification for TIA patients. These advancements not only improve clinical efficacy but also contribute to the anticipated market growth, with projections indicating a rise to 0.38 USD Billion by 2035.

    Market Segment Insights

    Regional Insights

    Key Companies in the Transient Ischemic Attack Market market include

    Industry Developments

    Future Outlook

    Transient Ischemic Attack Market Future Outlook

    The Global Transient Ischemic Attack Market is projected to grow at an 11.0% CAGR from 2024 to 2035, driven by advancements in diagnostics, increasing awareness, and enhanced treatment options.

    New opportunities lie in:

    • Develop AI-driven diagnostic tools to improve early detection of TIAs.
    • Invest in telehealth solutions for remote monitoring and patient management.
    • Create targeted therapies focusing on high-risk populations to enhance treatment efficacy.

    By 2035, the market is expected to achieve substantial growth, reflecting advancements in treatment and increased patient engagement.

    Market Segmentation

    Market Segmentation

    Transient Ischemic Attack Market, by Region
    • Americas
    • North America
    • US
    • Canada
    • Latin America
    • Europe
    • Western Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Western Europe
    • Eastern Europe
    • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
    • Middle East & Africa
    • Middle East
    • Africa
    Transient Ischemic Attack Market, by End-User
    • Hospitals & Clinics
    • Diagnostic Centers
    • Research Laboratories
    Transient Ischemic Attack Market, by Diagnosis
    • Imaging Techniques
    • Computed Tomography (CT) scan
    • Carotid Duplex Scanning
    • Magnetic Resonance Imaging
    • Echocardiography            
    Transient Ischemic Attack Market, by Treatment
    • Surgery
    • Drugs
    • Antithrombotic agents
    • Antiplatelets
    • Clopidogrel
    • Aspirin
    • Heparins
    • ENOXAPARIN
    • DALTEPARIN
    • Fibrinolytics
    • Tenecteplase
    Transient Ischemic Attack Market, by Age Groups
    • 0–18 years
    • 19–40 years (Millennial)
    • 41–60 years
    • 60+ years

    Report Scope

    Attribute/Metric Details
    Market Size 2030  USD 0.29 Billion 2032
    Compound Annual Growth Rate (CAGR) 9.34% 2032
    Base Year 2021
    Market Forecast Period 2024-2032
    Historical Data 2018 - 2021
    Market Forecast Units Value (USD Million)
    Report Coverage Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Segments Covered Product, technology, application, and end-users.
    Geographies Covered Americas, Europe, Asia Pacific and the Middle East and Africa
    Countries Covered China, Japan, India, Australia, South Korea, Australia, Rest of Asia-Pacific
    Key Companies Profiled Koninklijke Philips NV (Netherlands), Stryker Corporation (US), Johnson & Johnson Services Inc (US), Boston Scientific Corporation (US), Sanofi (France), Bayer AG (Germany), Pfizer Inc (US), Siemens AG (US), F. Hoffmann-La Roche AG (Switzerland), GE Healthcare (UK), Penumbra Inc (California), Medtronic PLC (Ireland), Abbott Laboratories (US), Merck & Co., Inc (US), and Boehringer Ingelheim GmbH (Germany).
    Key Market Opportunities Key market opportunities for the Transient Ischemic Attack market include the development of advanced diagnostic tools, innovative treatment options, and personalized medicine approaches to improve early detection and patient outcomes.
    Key Market Dynamics   The key market dynamics for the transient ischemic attack (TIA) market include increasing incidence rates, advances in diagnostic and therapeutic technologies, growing awareness and early intervention, and substantial investment in research and development.

    Market Highlights

    Author

    Rahul Gotadki
    Assistant Manager

    She holds an experience of about 6+ years in market research and business consulting, working under the spectrum of information communication technology, telecommunications and semiconductor domains. aarti conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. her expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

    Leave a Comment

    Latest Comments

    John Doe
    john@example.com

    This is a great article! Really helped me understand the topic better.

    Posted on July 23, 2025, 10:15 AM
    Jane Smith
    jane@domain.com

    Thanks for sharing this. I’ve bookmarked it for later reference.

    Posted on July 22, 2025, 7:45 PM

    FAQs

    At what CAGR is the global transient ischemic attack market projected to grow in the forecast period (2024-2032)?

    Transient ischemic attack market projected to grow at approximately 9.24% CAGR during the assessment period (2024-2032).

    How much is the global transient ischemic attack market worth in the future?

    The valuation of the global transient ischemic attack market is estimated to increase to USD 0.29 Billion by the end of 2032.

    What are the major tailwinds pushing the growth of the global transient ischemic attack market?

    Rising need for better treatment due to the increasing prevalence of neurological disorders and increasing R&D investments in biotechnology and pharmaceutical sectors are major tailwinds pushing the growth of the global transient ischemic attack market.

    Which region holds the largest share in the global transient ischemic attack market?

    North America holds the largest share in the global transient ischemic attack market, followed by Europe and the Asia Pacific, respectively.

    Who are the top players in the global transient ischemic attack market?

    EnteroMedics Inc. (U.S.), ElectroCore Medical LLC (U.S.), LivaNova PLC (U.K), Cyberonics, Inc. (US), NeuroMetrix, Inc.(U.S.), Boston Scientific Corporation (US), Inspire Medical Systems Inc.(U.S.), Electrical Geodesics Inc. (U.S.), ImThera Medical (U.S.), Nihon Kohden Corporation (Japan), Esaote (Italy), Masimo Corporation (U.S.), and Hologic (U.S.), are some of the top players operating in the global transient ischemic attack market.

    1. Report Prologue
    2. Executive Summary
    3. Market Introduction
      1. Definition 26
      2. Scope Of Study 26
      3. List Of Assumptions 26
      4. Market Structure 27
    4. Research Methodology
      1. Research Process 29
      2. Primary Research 30
      3. Secondary Research 31
      4. Market Size Estimation 32
      5. Forecast Model 32
    5. Market Dynamics
      1. Introduction 34
      2. Drivers 35
        1. Increasing Preference For Minimally Invasive Procedures 35
        2. Rising Prevalence Of Chronic Disorders 36
        3. Improvement In Reimbursement Scenario 37
        4. Rising Geriatric Population 38
      3. Restraints 39
        1. Rising Treatment Cost And Hospital Stay 39
        2. Lack Of Skilled Physicians 40
      4. Opportunities 41
        1. New Advancements In Catheterization Devices 41
        2. Guide Wire Assisted Surgery In Elderly Population 41
      5. Mega Trends 41
        1. Telemedicine 41
      6. Macroeconomic Indicators 41
      7. Technology Trends & Assessment 42
    6. Market Factor Analysis
      1. Porter’s Five Forces Model 44
        1. Threat Of New Entrants 44
        2. Bargaining Power Of Suppliers 44
        3. Threat Of Substitutes 45
        4. Bargaining Power Of Buyers 45
        5. Intensity Of Rivalry 45
      2. Supply Chain Analysis 46
        1. Research &Development 46
        2. Manufacturing 46
        3. Distribution 46
        4. Marketing & Sales 47
        5. Post-Sales Monitoring 47
      3. Demand & Supply: Gap Analysis 47
      4. Pricing Analysis 47
      5. Investment Feasibility Analysis 47
    7. Global Transient Ischemic Attack Market, By Diagnosis
      1. Introduction 49
      2. Imaging Techniques 49
        1. Computed Tomography (CT) Scan 51
        2. Carotid Duplex Scanning 51
        3. Magnetic Resonance Imaging 52
        4. Echocardiography 52
    8. Global Transient Ischemic Attack Market, By Treatment
      1. Introduction 54
      2. Surgery 54
      3. Drugs 54
        1. Surgery 55
        2. Drugs 56
    9. Global Transient Ischemic Attack Market, By Age Groups
      1. Introduction 62
      2. 0–18 Years 62
      3. 19–40 Years (Millennial) 62
      4. 41–60 Years 62
      5. 60+ Years 63
        1. 0-18 Years 64
        2. 19-40 Years 65
        3. 41-60 Years 65
        4. 60+ Years 65
    10. Global Transient Ischemic Attack Market, By End-User
      1. Introduction 67
      2. Hospitals & Clinics 67
      3. Diagnostic Centers 67
      4. Research Laboratories 68
        1. Hospitals 69
        2. Diagnostic Centers 70
        3. Research Laboratories 70
    11. Global Transient Ischemic Attack Market, By Region
      1. Introduction 72
      2. Americas 73
        1. North America 78
        2. South America 90
      1. Europe 94
        1. Western Europe 99
        2. Eastern Europe 127
      2. Asia Pacific 131
        1. Asia Pacific 132
        2. Japan 136
        3. China 140
        4. India 144
        5. Australia 148
        6. Republic Of Korea 152
        7. Rest Of Asia Pacific 156
      3. The Middle East & Africa 160
        1. Middle East And Africa 161
        2. United Arab Emirates 164
        3. Saudi Arabia 168
        4. Rest Of Middle East & Africa 172
    12. Competitive Landscape
      1. Company Market Share Analysis 177
        1. Introduction 177
      2. Company Share Analysis 178
      3. Recent Developments, 2013–2018 179
    13. Company Profiles
      1. Koninklijke Philips N.V. 184
        1. Company Overview 184
        2. Financial Overview 184
        3. Products Offering 185
        4. Key Developments 185
        5. SWOT Analysis 185
        6. Key Strategy 186
      2. Stryker Corporation 187
        1. Company Overview 187
        2. Financial Overview 187
        3. Products Offering 188
        4. Key Developments 188
        5. SWOT Analysis 189
        6. Key Strategy 189
      3. Johnson & Johnson Services Inc. 190
        1. Company Overview 190
        2. Financial Overview 190
        3. Products Offering 191
        4. Key Developments 191
        5. SWOT Analysis 192
        6. Key Strategy 192
      4. Boston Scientific Corporation 193
        1. Company Overview 193
        2. Financial Overview 193
        3. Products Offering 194
        4. Key Developments 195
        5. SWOT Analysis 195
        6. Key Strategy 195
      5. Sanofi 196
        1. Company Overview 196
        2. Financial Overview 196
        3. Products Offering 197
        4. Key Developments 197
        5. SWOT Analysis 197
        6. Key Strategy 197
      6. Bayer AG 198
        1. Company Overview 198
        2. Financial Overview 198
        3. Products Offering 199
        4. Key Developments 199
        5. SWOT Analysis 199
        6. Key Strategy 199
      7. Pfizer Inc. 200
        1. Company Overview 200
        2. Financial Overview 200
        3. Products Offering 201
        4. Key Developments 201
        5. SWOT Analysis 201
        6. Key Strategy 201
      8. Siemens AG 202
        1. Company Overview 202
        2. Financial Overview 202
        3. Products Offering 203
        4. Key Developments 203
        5. SWOT Analysis 203
        6. Key Strategy 203
      9. F. Hoffmann-La Roche AG 204
        1. Company Overview 204
        2. Financial Overview 204
        3. Products Offering 205
        4. Key Developments 205
        5. SWOT Analysis 205
        6. Key Strategy 205
      10. GE Healthcare 206
        1. Company Overview 206
        2. Financial Overview 206
        3. Products Offering 207
        4. Key Developments 207
        5. SWOT Analysis 207
        6. Key Strategy 207
      11. Penumbra, Inc. 208
        1. Company Overview 208
        2. Financial Overview 208
        3. Products Offering 209
        4. Key Developments 209
        5. SWOT Analysis 209
        6. Key Strategy 210
      12. Medtronic PLC 211
        1. Company Overview 211
        2. Financial Overview 211
        3. Products Offering 212
        4. Key Developments 212
        5. SWOT Analysis 212
        6. Key Strategy 213
      13. Abbott Laboratories 214
        1. Company Overview 214
        2. Financial Overview 214
        3. Products Offering 215
        4. Key Developments 215
        5. SWOT Analysis 216
        6. Key Strategy 216
      14. Merck & Co., Inc. 217
        1. Company Overview 217
        2. Financial Overview 217
        3. Products Offering 218
        4. Key Developments 218
        5. SWOT Analysis 218
        6. Key Strategy 218
      15. Boehringer Ingelheim GmbH 219
        1. Company Overview 219
        2. Financial Overview 219
        3. Products Offering 220
        4. Key Developments 220
        5. SWOT Analysis 220
        6. Key Strategy 220
    14. Conclusion
      1. Key Findings 222
        1. CEO’s Viewpoint 222
        2. Unmet Needs 222
        3. Key Companies To Watch 222
        4. Prediction 222
    15. Appendix
      1. Discussion Blue Print 224
      2. References 225
    16. List of Tables and Figures
      1. 16 List Of Tables
      2. TABLE 1 MARKET SYNOPSIS 24
      3. TABLE 2 LIST OF ASSUMPTIONS 26
      4. TABLE 3 PRIMARY INTERVIEWS 30
      5. TABLE 4 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 50
      6. TABLE 5 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUES, 2020–2027 (USD MILLION) 50
      7. TABLE 6 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR IMAGING TECHNIQUES, BY COMPUTED TOMOGRAPHY (CT) SCAN, 2020–2027 (USD MILLION) 51
      8. TABLE 7 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR IMAGING TECHNIQUES, BY CAROTID DUPLEX SCANNING, 2020–2027 (USD MILLION) 51
      9. TABLE 8 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR IMAGING TECHNIQUES, BY MAGNETIC RESONANCE IMAGING, 2020–2027 (USD MILLION) 52
      10. TABLE 9 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR IMAGING TECHNIQUES, BY ECHOCARDIOGRAPHY, 2020–2027 (USD MILLION) 52
      11. TABLE 10 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY TREATMENT, 2020–2027 (USD MILLION) 55
      12. TABLE 11 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY SURGERY, 2020–2027 (USD MILLION) 55
      13. TABLE 12 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 56
      14. TABLE 13 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUG, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 56
      15. TABLE 14 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS, 2020–2027 (USD MILLION) 56
      16. TABLE 15 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTIPLATELETS, BY CLOPIDOGREL, 2020–2027 (USD MILLION) 57
      17. TABLE 16 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTIPLATELETS, BY ASPIRIN, 2020–2027 (USD MILLION) 57
      18. TABLE 17 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 57
      19. TABLE 18 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR HEPARINS, BY ENOXAPARIN, 2020–2027 (USD MILLION) 58
      20. TABLE 19 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR HEPARINS, BY DALTEPARIN, 2020–2027 (USD MILLION) 58
      21. TABLE 20 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS, 2020–2027 (USD MILLION) 58
      22. TABLE 21 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR FIBRINOLYTICS, BY TENECTEPLASE, 2020–2027 (USD MILLION) 59
      23. TABLE 22 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR FIBRINOLYTICS, BY ALTEPLASE 2020–2027 (USD MILLION) 59
      24. TABLE 23 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 59
      25. TABLE 24 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTIHYPERTENSIVE AGENTS, BY PRAZOSIN, 2020–2027 (USD MILLION) 60
      26. TABLE 25 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTIHYPERTENSIVE AGENTS, BY MOXONIDINE, 2020–2027 (USD MILLION) 60
      27. TABLE 26 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUPS, 2020–2027 (USD MILLION) 63
      28. TABLE 27 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY 0-18 YEARS, 2020–2027 (USD MILLION) 64
      29. TABLE 28 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY 19-40 YEARS, 2020–2027 (USD MILLION) 65
      30. TABLE 29 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY 41-60 YEARS, 2020–2027 (USD MILLION) 65
      31. TABLE 30 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR AGE GROUP, BY 60+ YEARS, 2020–2027 (USD MILLION) 65
      32. TABLE 31 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 68
      33. TABLE 32 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR HOSPITALS, BY REGION, 2020–2027 (USD MILLION) 69
      34. TABLE 33 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSTIC CENTERS, BY REGION, 2020–2027 (USD MILLION) 70
      35. TABLE 34 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET FOR RESEARCH LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 70
      36. TABLE 35 GLOBAL TRANSIENT ISCHEMIC ATTACK MARKET, BY REGION, 2020–2027 (USD MILLION) 72
      37. TABLE 36 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET, BY REGION, 2020–2027 (USD MILLION) 73
      38. TABLE 37 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 74
      39. TABLE 38 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 74
      40. TABLE 39 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027 (USD MILLION) 74
      41. TABLE 40 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 75
      42. TABLE 41 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 75
      43. TABLE 42 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS, 2020–2027 (USD MILLION) 75
      44. TABLE 43 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 76
      45. TABLE 44 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS, 2020–2027 (USD MILLION) 76
      46. TABLE 45 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 76
      47. TABLE 46 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 77
      48. TABLE 47 AMERICAS TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 77
      49. TABLE 48 NORTH AMERICA: TRANSIENT ISCHEMIC ATTACK MARKET, BY COUNTRY, 2020-2027 (USD MILLION) 78
      50. TABLE 49 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 78
      51. TABLE 50 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 79
      52. TABLE 51 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 79
      53. TABLE 52 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 79
      54. TABLE 53 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 80
      55. TABLE 54 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS, 2020–2027 (USD MILLION) 80
      56. TABLE 55 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 80
      57. TABLE 56 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS, 2020–2027 (USD MILLION) 81
      58. TABLE 57 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 81
      59. TABLE 58 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 81
      60. TABLE 59 NORTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 82
      61. TABLE 60 U.S. TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 82
      62. TABLE 61 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 82
      63. TABLE 62 U.S. TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027 (USD MILLION) 83
      64. TABLE 63 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 83
      65. TABLE 64 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS 2020–2027 (USD MILLION) 83
      66. TABLE 65 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS, 2020–2027 (USD MILLION) 84
      67. TABLE 66 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 84
      68. TABLE 67 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS, 2020–2027 (USD MILLION) 84
      69. TABLE 68 U.S. TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 85
      70. TABLE 69 U.S. TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 85
      71. TABLE 70 U.S. TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 85
      72. TABLE 71 CANADA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 86
      73. TABLE 72 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 86
      74. TABLE 73 CANADA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027 (USD MILLION) 86
      75. TABLE 74 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 87
      76. TABLE 75 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 87
      77. TABLE 76 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS, 2020–2027 (USD MILLION) 87
      78. TABLE 77 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 88
      79. TABLE 78 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS, 2020–2027 (USD MILLION) 88
      80. TABLE 79 CANADA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 88
      81. TABLE 80 CANADA TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 89
      82. TABLE 81 CANADA TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 89
      83. TABLE 82 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 90
      84. TABLE 83 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 90
      85. TABLE 84 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 90
      86. TABLE 85 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 91
      87. TABLE 86 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 91
      88. TABLE 87 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS, 2020–2027 (USD MILLION) 91
      89. TABLE 88 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 92
      90. TABLE 89 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS, 2020–2027 (USD MILLION) 92
      91. TABLE 90 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 92
      92. TABLE 91 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 93
      93. TABLE 92 SOUTH AMERICA TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 93
      94. TABLE 93 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 94
      95. TABLE 94 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 95
      96. TABLE 95 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 95
      97. TABLE 96 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027 (USD MILLION) 95
      98. TABLE 97 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 96
      99. TABLE 98 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 96
      100. TABLE 99 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS, 2020–2027 (USD MILLION) 96
      101. TABLE 100 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 97
      102. TABLE 101 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS, 2020–2027 (USD MILLION) 97
      103. TABLE 102 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 97
      104. TABLE 103 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 98
      105. TABLE 104 EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 98
      106. TABLE 105 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 99
      107. TABLE 106 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 99
      108. TABLE 107 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 99
      109. TABLE 108 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 100
      110. TABLE 109 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 100
      111. TABLE 110 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS, 2020–2027 (USD MILLION) 100
      112. TABLE 111 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 101
      113. TABLE 112 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS, 2020–2027 (USD MILLION) 101
      114. TABLE 113 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 101
      115. TABLE 114 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 102
      116. TABLE 115 WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 102
      117. TABLE 116 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 103
      118. TABLE 117 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 103
      119. TABLE 118 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 103
      120. TABLE 119 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 104
      121. TABLE 120 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 104
      122. TABLE 121 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS, 2020–2027 (USD MILLION) 104
      123. TABLE 122 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 105
      124. TABLE 123 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS, 2020–2027 (USD MILLION) 105
      125. TABLE 124 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 105
      126. TABLE 125 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 106
      127. TABLE 126 GERMANY TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 106
      128. TABLE 127 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 107
      129. TABLE 128 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 107
      130. TABLE 129 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 107
      131. TABLE 130 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 108
      132. TABLE 131 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 108
      133. TABLE 132 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS, 2020–2027 (USD MILLION) 108
      134. TABLE 133 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 109
      135. TABLE 134 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS, 2020–2027 (USD MILLION) 109
      136. TABLE 135 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 109
      137. TABLE 136 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 110
      138. TABLE 137 FRANCE TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 110
      139. TABLE 138 U.K TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 111
      140. TABLE 139 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 111
      141. TABLE 140 U.K TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027 (USD MILLION) 111
      142. TABLE 141 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 112
      143. TABLE 142 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 112
      144. TABLE 143 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS, 2020–2027 (USD MILLION) 112
      145. TABLE 144 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 113
      146. TABLE 145 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS, 2020–2027 (USD MILLION) 113
      147. TABLE 146 U.K TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 113
      148. TABLE 147 U.K TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 114
      149. TABLE 148 U.K TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 114
      150. TABLE 149 ITALY TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 115
      151. TABLE 150 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 115
      152. TABLE 151 ITALY TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 115
      153. TABLE 152 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 116
      154. TABLE 153 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS 2020–2027 (USD MILLION) 116
      155. TABLE 154 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS, 2020–2027 (USD MILLION) 116
      156. TABLE 155 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 117
      157. TABLE 156 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS, 2020–2027 (USD MILLION) 117
      158. TABLE 157 ITALY TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 117
      159. TABLE 158 ITALY TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 118
      160. TABLE 159 ITALY TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 118
      161. TABLE 160 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 119
      162. TABLE 161 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 119
      163. TABLE 162 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT,, 2020–2027 (USD MILLION) 119
      164. TABLE 163 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 120
      165. TABLE 164 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 120
      166. TABLE 165 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS, 2020–2027 (USD MILLION) 120
      167. TABLE 166 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 121
      168. TABLE 167 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS, 2020–2027 (USD MILLION) 121
      169. TABLE 168 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 121
      170. TABLE 169 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 122
      171. TABLE 170 SPAIN TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 122
      172. TABLE 171 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 123
      173. TABLE 172 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 123
      174. TABLE 173 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET BY TREATMENT, 2020–2027 (USD MILLION) 123
      175. TABLE 174 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR TREATMENT, BY DRUGS, 2020–2027 (USD MILLION) 124
      176. TABLE 175 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTITHROMBOTIC AGENTS, 2020–2027 (USD MILLION) 124
      177. TABLE 176 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY ANTIPLATELETS, 2020–2027 (USD MILLION) 124
      178. TABLE 177 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY HEPARINS, 2020–2027 (USD MILLION) 125
      179. TABLE 178 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR ANTITHROMBOTIC AGENTS, BY FIBRINOLYTICS, 2020–2027 (USD MILLION) 125
      180. TABLE 179 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DRUGS, BY ANTIHYPERTENSIVE AGENTS, 2020–2027 (USD MILLION) 125
      181. TABLE 180 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY AGE GROUP, 2020–2027 (USD MILLION) 126
      182. TABLE 181 REST OF WESTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY END-USER, 2020–2027 (USD MILLION) 126
      183. TABLE 182 EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET, BY DIAGNOSIS, 2020–2027 (USD MILLION) 127
      184. TABLE 183 EASTERN EUROPE TRANSIENT ISCHEMIC ATTACK MARKET FOR DIAGNOSIS, BY IMAGING TECHNIQUE, 2020–2027 (USD MILLION) 127
      185. TABLE 184 EASTERN EUROPE TRANSIENT ISCHE

    Transient Ischemic Attack Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials